Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone.

Ondrej Majek Jakub GregorNesrin MogulkoćKatarzyna LewandowskaMartina ŠterclováVeronika MüllerMarta HájkováMordechai R KramerJasna Tekavec-TrkanjecDragana JovanovićMichael StudnickaNatalia StoevaKlaus-Uwe KirchgässlerSimona LittnerováLadislav DušekMartina Koziar Vasakova

Published in: PloS one (2022)

This EMPIRE analysis confirms the favourable outcomes observed for pirfenidone treatment in patients with definitive IPF and indicates benefits also for patients with probable or possible IPF.

Keyphrases

idiopathic pulmonary fibrosis
lung function
interstitial lung disease
cystic fibrosis
air pollution
chronic obstructive pulmonary disease
rheumatoid arthritis
type diabetes
adipose tissue
systemic sclerosis
weight loss